Investigation of MHR-nephropathy relationship and the effect of SGLT2is on MHR in patients with type 2 diabetes

Tekin, Bedriye Gizem; Pektaş, Erengül

doi:10.1007/s11845-024-03638-0

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that the use of SGLT2i leads to a decrease in the development of cardiovascular complications in patients with T2D, reducing arterial stiffness, reducing endothelial dysfunction, and increasing shear stress and blood viscosity; it has also been reported that SGLT2i can lead to a reduction in the monocyte/high-density lipoprotein (HDL) ratio (MHR), decreasing the inflammation and oxidative stress, thus leading to both renoprotective and cardioprotective effects [ 14 , 23 ]. Moreover, it has been shown that after 2 days of treatment with dapagliflozin, patients had a significant increase in FMD of 1.2% (from 2.8 to 4.0%), while in our study, we found an improvement of 0.91% (from 6.51 to 7.42%) in the group of patients receiving dapagliflozin, whereas in the group of patients receiving empagliflozin, the improvement was 2.6% (from 4.62 to 7.22%).…”

Section: Discussionmentioning

confidence: 99%

Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial

Balleza Alejandri,

Grover Páez,

González Campos

et al. 2024

JCDD

View full text Add to dashboard Cite

Aim: To assess the acute effect of empagliflozin versus dapagliflozin administration on flow-mediated vasodilation in patients with type 2 diabetes mellitus. Design: A double-blind clinical trial, at the Experimental and Clinical Therapeutics Institute, University Health Sciences Center, at the Universidad de Guadalajara, in inpatients with T2D according to the 2023 ADA criteria. Methods: Thirty patients (15 males and 15 females), aged between 35 and 65 years, were included in this study, according to the 2023 ADA criteria. The eligible patients were randomly assigned to three groups: empagliflozin 25 mg once daily, dapagliflozin 10 mg once daily, or placebo once daily. Anthropometric parameters were taken using validated techniques. FMD was measured using a high-resolution semiautomatic ultrasound UNEX-EF 38G (UNEX Co., Ltd., Nagoya, Japan). Arterial tension was determined with the OMRON electronic digital sphygmomanometer (HEM 907 XL, Kyoto, Japan). Results: The group of patients who received empagliflozin had a significantly lower baseline flow-mediated dilation (FMD) compared to the group receiving dapagliflozin (p = 0.017); at the end of this study, the empagliflozin group achieved a comparable FMD to the dapagliflozin group (p = 0.88). Conclusion: After the treatment period, the empagliflozin and dapagliflozin groups achieved similar FMD, suggesting a class effect.

show abstract

Section: Discussionmentioning

confidence: 99%